Mecasermin

Eton Pharmaceuticals acquired Increlex®, a biologic treatment for severe primary insulin-like growth factor 1 deficiency in pediatric patients, expanding its pediatric endocrinology portfolio. Increlex® is now available in the U.S. through AnovoRx, a specialty pharmacy for rare and chronic conditions, and will be commercialized by Eton after a six-month transition period.

Eton Pharmaceuticals appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer, leveraging her extensive experience in pharmaceutical sales, marketing, and pediatric endocrinology to drive growth with upcoming product launches.

Ipsen reports YTD 2024 total sales growth of 9.2% at CER, driven by Dysport, Cabometyx, and Bylvay. Regulatory approvals for Iqirvo and Kayfanda, and increased 2024 guidance: total-sales growth >8.0% at CER, core operating margin >31.0%.

Eton Pharmaceuticals to acquire Increlex® from Ipsen, aligning with its mission to develop life-changing treatments for ultra-rare conditions. Increlex treats severe IGF-1 deficiency in children and adolescents, approved in 40 territories. Eton will commercialize in the U.S. immediately, with a six-month transition period outside the U.S. Financed by Eton’s cash and credit facility expansion, Ipsen reported €17.3 million in global sales for Increlex in 2023.

The article discusses challenges in treating CNS diseases due to the BBB's protective mechanisms, limiting drug delivery. It explores invasive and non-invasive strategies for drug delivery, including intrathecal administration, microneedles, and non-invasive methods like passive transcytosis, intranasal administration, and BBB disruption techniques using light and ultrasound. Ligands conjugation and membrane coating are also highlighted for targeted drug delivery to the brain.